New Study Shows Chemotherapy Can Limit Recurrence Of Testicular Cancer

New Study Shows Chemotherapy Can Limit Recurrence Of Testicular Cancer

We’re learning more about treatments for testicular cancer every year, and a recent study indicates that one of the most common methods used to eliminate cancerous cells could have a long-term benefit in preventing cancer from returning. Chemotherapy, which involves the infusion of intracellular poisons to kill the malevolent, unwanted cells. There are obvious side effects, including hair loss, but it has proven to be a reliable and relatively safe method of treatment.

But the long-term results of chemotherapy have not been studied in detail. This new study from the University Hospital of North Norway used a population-based cohort to examine past testicular cancer patients. They found that there was a fairly significant recurrence gap in between people who had chemotherapy and patients who had purely surgical or radiation-based treatments. Use of cisplatin-based chemotherapy was connected with a 45% reduction in the risk of developing testicular cancer again.

Norway’s Cancer Registry is one of the country’s greatest diagnostic tools, a massive repository of information that allows scientists to access information about past patients and draw connections. The study found that the average percentage of second testicular cancers in treated patients was 4%, but patients who had been treated with chemotherapy saw that number drop to 2.8%.

It’s a promising figure, and hopefully will spur more research into the long-term effects of the practice.

Read more at the Urology Times.